AccessibilityHelpAbout Us
Xtl Biopharmaceuticals logo

Xtl Biopharmaceuticals(NASDAQ) XTLB

Market Cap$10.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-100%
5 Year-86%
1 Year-50%
1 Month-26%
$2.40
+0.42%
+0.01Today
Xtl Biopharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 2.402026-09-17
Xtl Biopharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.76%USD 2.522026-09-10
1 month-25.7%USD 3.232026-08-18
3 month-5.51%USD 2.542026-06-18
Year to date+3.45%USD 2.322025-12-31
1 year-50%USD 4.802025-09-17
3 year-39.39%USD 3.962023-09-15
5 year-85.78%USD 16.882021-09-17
Since inception-99.9%USD 2,284.002005-09-01

Xtl Biopharmaceuticals Financials at a Glance

Market Cap

$10.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$451.00K

Net Income (TTM)

-$1.03M

EPS (TTM)

$0.00

P/E Ratio

-5.34

Dividend

$0.00

Beta (Volatility)

0.57 (Low)

Price

$2.40

Volume

2,996

Open

$2.40

Previous Close

$2.40

Daily Range

$2.35 - $2.40

52-Week Range

$2.01 - $10.28

Estimated Earnings Date

Apr 29, 2026

XTLB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xtl Biopharmaceuticals

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm focused on developing innovative drug therapies for autoimmune diseases. The company's lead investigational compound, hCDR1, is advancing towards Phase II trials, targeting systemic lupus erythematosus and Sjogren's syndrome.

Products and Services
  • hCDR1, an investigational drug for autoimmune conditions
  • Licensing agreement with Yeda Research for drug development
  • Research and development in novel therapeutic areas
Growth Outlook
  • hCDR1 poised to enter Phase II trials, enhancing market potential
  • Strong pipeline with multiple therapeutic indications under exploration
  • Strategic partnerships to bolster research and development efforts
Financial Highlights
  • Recent quarterly revenue of $289,000, showing growth potential
  • Cash and short-term investments totaled $1,143,000 as of Q4 2024
  • Net income for Q4 2024 was -$255,000, reflecting ongoing investment in R&D
XTL Biopharmaceuticals Ltd. operates in the biotechnology sector, with a commitment to addressing unmet medical needs in autoimmune diseases. The company has a significant focus on research and development, particularly with its lead compound, hCDR1, which is expected to enter Phase II trials. This advancement could position the company favorably within the competitive landscape of biopharmaceuticals. The growth outlook remains promising, driven by the potential of hCDR1 and the strategic partnerships that enhance its research capabilities. Financially, the company is navigating through a phase of investment, as indicated by the recent quarterly revenue and net income figures. The cash reserves provide a buffer for ongoing operations and development activities, suggesting a proactive approach to funding future growth. Overall, XTL Biopharmaceuticals Ltd. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in companies focused on innovative therapies for autoimmune conditions.
AI Generated • Sep 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

Shlomo Spokone Shalev, MBA

Website

www.xtlbio.com

Headquarters

Herzliya, TA 4676670, IL

XTLB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-269.02%

Return on Capital

-11253.33%

Return on Assets

-4198.19%

Earnings Yield

-18.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.24M

Volume

3.00K

Avg. Volume

69.92K

Financials (TTM)

Gross Profit

$119.00K

Operating Income

-$2.17M

EBITDA

-$791.25K

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$144.00K

Total Debt

$269.00K

Xtl Biopharmaceuticals Performance Analysis

Xtl Biopharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Xtl Biopharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-3178.4%
Q42025-12-31N/A
Xtl Biopharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.98N/A
20232023-12-31USD -1.3032.6%
20242024-12-31USD -0.61-52.9%
20252025-12-31USD -0.34-44.3%
Xtl Biopharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-244.4%
Q32024-09-3023.1%
Q42024-12-3160.0%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$289.00K

N/A

Gross Profit

-$43.00K

N/A

Gross Margin

-14.88%

N/A

Market Cap

$10.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.01M

N/A

Employees

10

N/A

Net Income

-$255.00K

+10.2%

EBITDA

-$429.25K

-51.1%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$144.00K

-93.8%

Total Debt

$269.00K

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$269.00K

N/A

Return on Assets

-41.98%

N/A

Return on Invested Capital

6.65%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KALAKALA BIO, Inc.
$0.56+8.24%
PLRZPolyrizon Ltd.
$11.03+3.57%
ENSCEnsysce Biosciences, Inc.
$0.45+1.05%
QNRXQuoin Pharmaceuticals, Ltd.
$7.01+1.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$108.80+7.67%
NOKNokia
$10.60+4.54%
DAICCid HoldCo
$5.30+163.68%
NVDANvidia
$219.34+2.54%

Questions About XTLB

What is the current price of Xtl Biopharmaceuticals?

Xtl Biopharmaceuticals is trading at $2.40 per share.

What is the 52-week range for Xtl Biopharmaceuticals?

Over the past 52 weeks, Xtl Biopharmaceuticals has traded between $2.01 and $10.28.

How much debt does Xtl Biopharmaceuticals have?

As of the most recent reporting period, Xtl Biopharmaceuticals reported total debt of $138.00K.

How much cash does Xtl Biopharmaceuticals have on hand?

Xtl Biopharmaceuticals reported $371.00K in cash and cash equivalents in its most recent financial results.

What is Xtl Biopharmaceuticals’s dividend yield?

Xtl Biopharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services